We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hikma Pharmaceuticals, based in Jordan, has announced plans to acquire Ribosepharm, an oncology sales and marketing division of German drugmaker Ratiopharm, for $45 million.
In a development likely to fuel the argument that Medicare and Medicaid need major overhauls, the Congressional Budget Office (CBO) is predicting that these programs will grow by 124 percent over the next 10 years, outpacing economic growth two to one.
The UK's National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of Roche's Avastin and Merck Pharmaceuticals' Erbitux for the treatment of metastatic colorectal cancer.
Kirin Brewery and Astellas Pharma, both based in Japan, announced that they have entered into a license and collaboration agreement under which the companies will develop and market a fully human anti-CD40 antagonistic monoclonal antibody.
Israeli drugmaker Compugen and Medarex announced they have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases.
U.S.-based Novavax announced this week that its virus-like particle (VLP) vaccines have been shown to be effective in generating protection against pandemic influenza as well as cross protection against different strains of the virus in preclinical studies.
Novartis' Lucentis has received approval in Europe as a new treatment for patients with wet age-related macular degeneration (AMD), the company announced.
Orchid Chemicals & Pharmaceuticals announced that its betalactam active pharmaceutical ingredient (API) facility in Aurangabad, India, has been approved by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
South African drugmaker Aspen Pharmacare and Lupin announced they have mutually agreed not to pursue the memorandum of understanding they signed in February 2006 for the development, manufacture and marketing of tuberculosis (TB) drugs.
An Ontario Superior Court judge has certified a class action lawsuit against Johnson & Johnson (J&J) and related companies on behalf of Canadians (excluding Quebec) who ingested the heartburn drug Prepulsid, according to the law firms representing the plaintiffs.